MX2023004518A - Compuestos espiro heterocíclicos y métodos de uso. - Google Patents

Compuestos espiro heterocíclicos y métodos de uso.

Info

Publication number
MX2023004518A
MX2023004518A MX2023004518A MX2023004518A MX2023004518A MX 2023004518 A MX2023004518 A MX 2023004518A MX 2023004518 A MX2023004518 A MX 2023004518A MX 2023004518 A MX2023004518 A MX 2023004518A MX 2023004518 A MX2023004518 A MX 2023004518A
Authority
MX
Mexico
Prior art keywords
methods
spiro compounds
heterocyclic spiro
compounds
heterocyclic
Prior art date
Application number
MX2023004518A
Other languages
English (en)
Inventor
David Huang
Brian Alan Lanman
Matthew R Kaller
Vu Van Ma
Dongcheng Dai
Alexander J Pickrell
Patricia Lopez
Nuria A Tamayo
Margaret Chu-Moyer
Abhisek Banerjee
Josephine Eshon
Heejun Lee
Francesco Manoni
Jose M Medina
John C Stellwagen
Zhen Sun
Wenhan Zhang
Kai Zhu
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MX2023004518A publication Critical patent/MX2023004518A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Abstract

La presente divulgación proporciona compuestos de Fórmula I que tienen actividad como inhibidores de la proteína mutante KRAS G12C. (ver fórmula) Esta divulgación también proporciona composiciones farmacéuticas que comprenden los compuestos, usos y métodos para tratar determinados trastornos, tales como el cáncer, que incluyen, pero sin limitación, cáncer de pulmón, cáncer de páncreas y cáncer colorrectal.
MX2023004518A 2020-10-20 2021-10-19 Compuestos espiro heterocíclicos y métodos de uso. MX2023004518A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2020122197 2020-10-20
PCT/CN2021/124598 WO2022083569A1 (en) 2020-10-20 2021-10-19 Heterocyclic spiro compounds and methods of use

Publications (1)

Publication Number Publication Date
MX2023004518A true MX2023004518A (es) 2023-06-19

Family

ID=81291543

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023004518A MX2023004518A (es) 2020-10-20 2021-10-19 Compuestos espiro heterocíclicos y métodos de uso.

Country Status (10)

Country Link
US (1) US20240059703A1 (es)
EP (1) EP4232444A1 (es)
JP (1) JP2023545545A (es)
AR (1) AR123848A1 (es)
AU (1) AU2021363262A1 (es)
CA (1) CA3198809A1 (es)
MX (1) MX2023004518A (es)
TW (1) TW202233629A (es)
UY (1) UY39477A (es)
WO (1) WO2022083569A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20230107642A1 (en) 2020-12-18 2023-04-06 Erasca, Inc. Tricyclic pyridones and pyrimidones
CR20230570A (es) 2021-05-05 2024-01-22 Revolution Medicines Inc Inhibidores de ras
WO2022235870A1 (en) 2021-05-05 2022-11-10 Revolution Medicines, Inc. Ras inhibitors for the treatment of cancer
WO2022266206A1 (en) 2021-06-16 2022-12-22 Erasca, Inc. Kras inhibitor conjugates

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201004200D0 (en) * 2010-03-15 2010-04-28 Univ Basel Spirocyclic compounds and their use as therapeutic agents and diagnostic probes
GB201504565D0 (en) * 2015-03-18 2015-05-06 Takeda Pharmaceutical Novel compounds
CN107814792B (zh) * 2016-09-14 2021-08-10 中国科学院上海药物研究所 一类喹唑啉衍生物、其组合物及用途
US20210317127A1 (en) * 2018-08-01 2021-10-14 Araxes Pharma Llc Heterocyclic spiro compounds and methods of use thereof for the treatment of cancer
JP2022505835A (ja) * 2018-10-24 2022-01-14 アラクセス ファーマ エルエルシー 腫瘍転移を阻害するためのｇ１２ｃ変異体ｋｒａｓタンパク質の阻害剤としての２－（２－アクリロイル－２，６－ジアザスピロ［３．４］オクタン－６－イル）－６－（１ｈ－インダゾール－４－イル）－ベンゾニトリル誘導体および関連化合物

Also Published As

Publication number Publication date
UY39477A (es) 2022-05-31
AR123848A1 (es) 2023-01-18
CA3198809A1 (en) 2022-04-28
AU2021363262A1 (en) 2023-06-08
EP4232444A1 (en) 2023-08-30
US20240059703A1 (en) 2024-02-22
TW202233629A (zh) 2022-09-01
JP2023545545A (ja) 2023-10-30
WO2022083569A1 (en) 2022-04-28

Similar Documents

Publication Publication Date Title
WO2020050890A3 (en) Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer
MX2023004518A (es) Compuestos espiro heterocíclicos y métodos de uso.
MX2020011907A (es) Inhibidores de kras g12c para el tratamiento de cancer.
MX2023004802A (es) Compuestos espiro heterocíclicos y métodos de uso.
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
MX2022004656A (es) Derivados de piridopirimidina utiles como inhibidores de kras g12c y kras g12d en el tratamiento del cancer.
CR20220584A (es) Inhibidores de kras tricíclicos fusionados
EA202092320A1 (ru) Гетеробициклические ингибиторы mat2a и способы использования для лечения злокачественной опухоли
MX2020012204A (es) Inhibidores de kras g12c para tratar el cáncer.
PH12020551927A1 (en) Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators
MX2021014177A (es) Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos.
PH12020551717A1 (en) Dual atm and dna-pk inhibitors for use in anti-tumor therapy
CA3139348A1 (en) Heterocyclic compounds, preparation methods and uses thereof
MD3755703T2 (ro) Derivați N-(fenil)-2-(fenil)pirimidin-4-carboxamidă și compuși înrudiți ca inhibitori HPK1 pentru tratarea cancerului
JOP20210317A1 (ar) مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان
CR20220169A (es) Heterociclos bicíclicos como inhibidores de fgfr
GEP20237560B (en) Fused pyrazine derivatives as a2a / a2b inhibitors
MX2017004234A (es) Inhibidor del egfr y preparacion y aplicacion del mismo.
JOP20210171A1 (ar) مثبطات أزا-غير متجانسة ثنائية الحلقة لـ mat2a وطرق الاستخدام لعلاج السرطان
ZA202104423B (en) Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer
TN2010000204A1 (en) Kinesin inhibitors as cancer therapeutics
AU2020281332A8 (en) Dna-dependent protein kinase inhibitor
MX2020010942A (es) Inhibidores dobles de atm y adn-pk para uso en terapias antitumorales.
MX2021002805A (es) Terapias de combinacion.
MX2022005749A (es) Inhibidores de egfr alostericos y metodos de uso de los mismos.